A Zyprexa warning includes information about the harmful side effects associated with this atypical antipsychotic prescription medication. Zyprexa (olanzapine) was approved by the FDA in 1996 to treat the adverse symptoms of schizophrenia and bipolar disorder.
Zyprexa, and other atypical antipsychotics, were originally developed to deliver relief from certain unfavorable psychological symptoms without the side effects associated with traditional schizophrenia and bipolar medications. Ironically, numerous Zyprexa warning statements have been issued, revealing that atypical antipsychotics also pose serious side effect risks.
The Japanese and British governments issued Zyprexa warning statements at least one year before the United States government chose to inform the public about the serious risks associated with Zyprexa use. In 2002, the British Medical Journal published a report about serious Zyprexa-related diabetes risks. This article found that schizophrenic patients who had taken Zyprexa were at a significantly greater risk of developing diabetes and related complications, compared to those not taking Zyprexa.
In July 2002, Duke University published a report that officially prompted the United States to issue its own Zyprexa warning. The Duke Study discovered nearly 300 cases of treatment-emergent diabetes in Zyprexa users. More than seventy percent of these Zyprexa victims developed diabetes with moderate weight gain within the first six months of Zyprexa use. In addition to diabetes, at least one hundred patients also developed ketoacidosis, a deadly complication of diabetes. Twenty two Zyprexa users suffered from pancreatitis and another twenty three died as a result of Zyprexa diabetes complications.
In response to these Duke findings, the FDA issued a Zyprexa warning to inform consumers about the serious and life-threatening diabetes risks associated with Zyprexa. It wasn't until September 2003 that the FDA ordered the addition of an official Zyprexa warning to all patient product information. This Zyprexa warning specifically addresses the risks of hyperglycemia, ketoacidosis, coma and death associated with Zyprexa-emergent Diabetes Mellitus.
The Zyprexa warning states that the exact relationship between diabetes and Zyprexa use is unknown. According to the Zyprexa warning, doctors should closely monitor all Zyprexa patients for changes in glucose control. The Zyprexa warning states that patients with a family history of diabetes may be at an increased risk for Zyprexa side effects. The Zyprexa warning lists excessive thirst, frequent urination, increased hunger, and weakness as some of the early signs of diabetes complications. When Zyprexa users present any of these symptoms, immediate medical treatment should be sought.
If you are concerned about, or have suffered, the risks listed in the Zyprexa warning, please contact us to speak with a qualified and experienced attorney who can determine your legal rights and options in a case to seek relief for your Zyprexa losses.